Top Markets
Coin of the day
Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc.

AGN
株式のランク #38375
Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company... Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
株価
$0.29357476
最終同期: 2026-05-14
時価総額
$1.02M
変化(1日)
1.27%
変化(1年)
-42.07%
CA
取引 Algernon Pharmaceuticals Inc. (AGN)

カテゴリー

Algernon Pharmaceuticals Inc.(AGN)の株価履歴
終値の最高値: $0.29 (2026-05-01)

終値の最安値: $169.74 (2016-02-01)
Algernon Pharmaceuticals Inc. の株価履歴(2016 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -22.61%
2025 16.84%
2024 -12.82%
2023 -88.01%
2022 -47.29%
2021 -85.85%
2020 524.96%
2019 -58.71%
2018 -64.50%
2017 5.94%
2016 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$505.24 29.45%
US
$846.09 29.68%
NL
$731.69 7.13%
CH
$1.07K -6.40%
KR
$251.82 11.25%
BE